• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 28th April 2010

Time Trade Off and Valuing Quality of Life

In an article in Health Economics, Prof Devlin and her co-authors demonstrate the promise of using Lead Time TTO to value health ‘state worse than death’. They demonstrate the potential advantages of the approach and identify important next steps in…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

In an article in Health Economics, Prof Devlin and her co-authors demonstrate the promise of using Lead Time TTO to value health ‘state worse than death’. They demonstrate the potential advantages of the approach and identify important next steps in developing the methodology.

NICE’s preferred means of measuring health-related changes in quality of life is the EQ-5D, valued using what is known as the ‘York MVH’ (Measurement and Valuation of Health) value set.  This lists the value for every health state defined by the five-dimension, three-level EQ-5D system.  These values were generated using the Time Trade Off (TTO) method. The values are anchored at 1 (full health) and 0 (dead), as is required in the estimation of Quality Adjusted Life Years (QALYs).

TTO works by asking people to imagine living in a given state of health for, say, ten years and then finding the shorter amount of time in full health that they value equally.  TTO is widely used to value health states – but there are some problems with it.  For example, when people are asked to consider very poor states of health – persistent extreme pain, for example – they may dislike them so much that they would trade off all their time in full health.  In other words, they would prefer to be dead.  This is a health ‘state worse than death’ (SWD).   Presumably, the value of that SWD is less than zero – but how much?

How to put an actual value on SWDs is not just an issue that appeals to theoreticians; it can seriously complicate the values that support access decisions.  Problems with conventional approaches to TTO measurement include shifting from one approach of questioning to another when an SWD arises, so the values may not ‘mean’ the same thing.   Arbitrary decisions about the research design and data transformation for negative values raise equally serious issues.

In a forthcoming article in Health Economics, Nancy Devlin and her co-authors report on initial efforts to refine and test the feasibility of a new TTO approach and to explore the characteristics of the valuation data it generates.  The principal innovation of the new method is to introduce a ‘lead time’ of full health that participants can trade to avoid SWDs.

Lead Time TTOs may help resolve both the practical and the conceptual difficulties that exist using current TTO methods for valuing both SWDs and SBDs (states better than death).  Comparing these results to current MVH values is not straightforward, but does suggest that introduction of lead time has a ‘complex effect on the distribution of overall values’.

The authors conclude that ‘the lead time TTO shows considerable promise as a simple to use, uniform method applicable to all states, which has the potential to avoid the problem in conventional TTO with exaggerated negative values and the requirement arbitrarily to transform those.’  The method reported in this paper is now being explored further in studies across Europe.

Editor’s note: This has been published as Devlin, N., Tsuchiya, A., Buckingham, K. and Tilling, C. (2011) A uniform time trade off method for states better and worse than dead: Feasibility study of the ‘lead time’ approach. Health Economics. 20(3), 348-361.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes

Related News

Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!